Table 3. Comparison of expression of autophagy markers LC3B and p62 in a primary resected EAC cohort and a subcohort of neo-adjuvant chemotherapy (nCTX) treated EAC cases with paclitaxel containing regimens.

Significance was set to 0.05. Statistically significant p-values are shown in bold.

LC3B dots	Treatment		Total
	Primary Resected	nCTX
Low	95 (83.3%)	19 (67.9%)	114 (80.3%)
High	19 (16.7%)	9 (32.1%)	28 (19.7%)
Total	114	28	142
p-value = 0.108
p62 dots	Treatment		Total
	Primary Resected	nCTX
Low	95 (83.3%)	9 (32.1%)	104 (73.2%)
High	19 (16.7%)	19 (67.9%)	38 (26.8%)
Total	114	28	142
p-value < 0.001
p62 cytoplasmic	Treatment		Total
	Primary Resected	nCTX
Low	86 (75.4%)	12 (42.9%)	98 (69.0%)
High	28 (24.6%)	16 (57.1%)	44 (31.0%)
Total	114	28	142
p-value < 0.001
p62 nuclear	Treatment		Total
	Primary Resected	nCTX
Low	58 (50.9%)	16 (57.1%)	74 (52.1%)
High	56 (49.1%)	12 (42.9%)	68 (47.9%)
Total	114	28	142
p-value = 0.674
p62 dots-cyto	Treatment		Total
	Primary Resected	nCTX
Low	76 (66.7%)	4 (14.3%)	80 (56.3%)
High	38 (33.3%)	24 (85.7%)	62 (43.7%)
Total	114	28	142
p-value < 0.001
LCB/p62	Treatment		Total
	Primary Resected	nCTX
LL	66 (57.9%)	3 (10.7%)	69 (48.6%)
LH	29 (25.4%)	16 (57.1%)	45 (31.7%)
HL	10 (8.8%)	1 (3.6%)	11 (7.7%)
HH	9 (7.9%)	8 (28.6%)	17 (12.0%)
Total	114	28	142
p-value < 0.001